220 related articles for article (PubMed ID: 25877545)
41. Encephalitis and myelitis associated with dengue viral infection clinical and neuroimaging features.
Wasay M; Channa R; Jumani M; Shabbir G; Azeemuddin M; Zafar A
Clin Neurol Neurosurg; 2008 Jun; 110(6):635-40. PubMed ID: 18467022
[TBL] [Abstract][Full Text] [Related]
42. Immune response to dengue virus and prospects for a vaccine.
Murphy BR; Whitehead SS
Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
[TBL] [Abstract][Full Text] [Related]
43. Dengue infection in patients presenting with neurological manifestations in a dengue endemic population.
Jackson ST; Mullings A; Bennett F; Khan C; Gordon-Strachan G; Rhoden T
West Indian Med J; 2008 Sep; 57(4):373-6. PubMed ID: 19566019
[TBL] [Abstract][Full Text] [Related]
44. Virus isolation for diagnosing dengue virus infections in returning travelers.
Teichmann D; Göbels K; Niedrig M; Sim-Brandenburg JW; Làge-Stehr J; Grobusch MP
Eur J Clin Microbiol Infect Dis; 2003 Nov; 22(11):697-700. PubMed ID: 14564538
[TBL] [Abstract][Full Text] [Related]
45. Dengue Antibody and Zika: Friend or Foe?
Durbin AP
Trends Immunol; 2016 Oct; 37(10):635-636. PubMed ID: 27599407
[TBL] [Abstract][Full Text] [Related]
46. Dengue antibodies in Polish travellers returning from the tropics. Evaluation of serological tests.
Goljan J; Myjak P; Nahorski W; Kubica-Biernat B; Felczak-Korzybska I; Kowalczyk D; Kuna A; Kotłowski A
Int Marit Health; 2010; 61(1):36-40. PubMed ID: 20496327
[TBL] [Abstract][Full Text] [Related]
47. Rhombencephalitis associated with Dengue fever.
Verma R; Bharti K; Mehta M; Bansod A
J Clin Virol; 2016 May; 78():99-101. PubMed ID: 27015434
[TBL] [Abstract][Full Text] [Related]
48. A novel mosquito ubiquitin targets viral envelope protein for degradation and reduces virion production during dengue virus infection.
Troupin A; Londono-Renteria B; Conway MJ; Cloherty E; Jameson S; Higgs S; Vanlandingham DL; Fikrig E; Colpitts TM
Biochim Biophys Acta; 2016 Sep; 1860(9):1898-909. PubMed ID: 27241849
[TBL] [Abstract][Full Text] [Related]
49. The dangers of accepting a single diagnosis: case report of concurrent Plasmodium knowlesi malaria and dengue infection.
Chong SE; Mohamad Zaini RH; Suraiya S; Lee KT; Lim JA
Malar J; 2017 Jan; 16(1):2. PubMed ID: 28049485
[TBL] [Abstract][Full Text] [Related]
50. Competitive advantage of a dengue 4 virus when co-infecting the mosquito Aedes aegypti with a dengue 1 virus.
Vazeille M; Gaborit P; Mousson L; Girod R; Failloux AB
BMC Infect Dis; 2016 Jul; 16():318. PubMed ID: 27390932
[TBL] [Abstract][Full Text] [Related]
51. Safety evaluation of chimeric Langat/Dengue 4 flavivirus, a live vaccine candidate against tick-borne encephalitis.
Pripuzova NS; Tereshkina NV; Gmyl LV; Dzhivanyan TI; Rumyantsev AA; Romanova LIu; Mustafina AN; Lashkevich VA; Karganova GG
J Med Virol; 2009 Oct; 81(10):1777-85. PubMed ID: 19697399
[TBL] [Abstract][Full Text] [Related]
52. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses.
Mackenzie JS; Gubler DJ; Petersen LR
Nat Med; 2004 Dec; 10(12 Suppl):S98-109. PubMed ID: 15577938
[TBL] [Abstract][Full Text] [Related]
53. [Advances in dengue virus research in Colombia: the role of cellular microRNAs as an anti-dengue virus response].
Castrillón-Betancur JC; Urcuqui-Inchima S
Rev Chilena Infectol; 2017 Apr; 34(2):143-148. PubMed ID: 28632829
[TBL] [Abstract][Full Text] [Related]
54. Co-positivity of anti-dengue virus and anti-Japanese encephalitis virus IgM in endemic area: co-infection or cross reactivity?
Singh KP; Mishra G; Jain P; Pandey N; Nagar R; Gupta S; Prakash S; Prakash O; Khan DN; Shrivastav S; Singh DD; Jain A
Asian Pac J Trop Med; 2014 Feb; 7(2):124-9. PubMed ID: 24461525
[TBL] [Abstract][Full Text] [Related]
55. Dengue viral infections.
Malavige GN; Fernando S; Fernando DJ; Seneviratne SL
Postgrad Med J; 2004 Oct; 80(948):588-601. PubMed ID: 15466994
[TBL] [Abstract][Full Text] [Related]
56. Flavivirus cross-reactivity in serological tests and Guillain-Barré syndrome in a hematopoietic stem cell transplant patient: A case report.
Raboni SM; Bonfim C; Almeida BM; Zanluca C; Koishi AC; Rodrigues PRVP; Kay CK; Ribeiro LL; Scola RH; Duarte Dos Santos CN
Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28306183
[TBL] [Abstract][Full Text] [Related]
57. A conceptual model for optimizing vaccine coverage to reduce vector-borne infections in the presence of antibody-dependent enhancement.
Tang B; Huo X; Xiao Y; Ruan S; Wu J
Theor Biol Med Model; 2018 Sep; 15(1):13. PubMed ID: 30173664
[TBL] [Abstract][Full Text] [Related]
58. Dengue vaccine: opportunities and challenges.
Hatch S; Mathew A; Rothman A
IDrugs; 2008 Jan; 11(1):42-5. PubMed ID: 18175262
[TBL] [Abstract][Full Text] [Related]
59. Lipids and flaviviruses, present and future perspectives for the control of dengue, Zika, and West Nile viruses.
Martín-Acebes MA; Vázquez-Calvo Á; Saiz JC
Prog Lipid Res; 2016 Oct; 64():123-137. PubMed ID: 27702593
[TBL] [Abstract][Full Text] [Related]
60. Infection of the central nervous system with dengue virus 3 genotype I causing neurological manifestations in Brazil.
Oliveira DB; Machado G; Almeida GM; Ferreira PC; Bonjardim CA; Trindade Gde S; Abrahão JS; Kroon EG
Rev Soc Bras Med Trop; 2016 Feb; 49(1):125-9. PubMed ID: 27163577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
